US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

151.69

+1.561.04%

Post-market: 151.700.0100+0.01%19:59 EDT

Volume:223.05K

Turnover:33.90M

Market Cap:2.19B

PE:-30.97

High:153.41

Open:150.14

Low:150.14

Close:150.13

52wk High:161.38

52wk Low:53.30

Shares:14.41M

Float Shares:8.40M

Volume Ratio:1.23

T/O Rate:2.66%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.8978

EPS(LYR):-3.7076

ROE:-46.63%

ROA:-22.05%

PB:10.08

PE(LYR):-40.91

Loading ...

Overview Company News Filings

Palvella Therapeutics - on Track to Submit Nda for Qtorin Rapamycin in Second Half of 2026

THOMSON REUTERS

Palvella Therapeutics Announces Completion of FDA Pre-Nda Meeting for Qtorin™ Rapamycin in Microcystic Lymphatic Malformations

THOMSON REUTERS

Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Palvella Therapeutics Inc : Stephens Raises Target Price to $229 From $220

THOMSON REUTERS

Mizuho Securities Sticks to Their Buy Rating for Palvella Therapeutics (PVLA)

Palvella Therapeutics issued patent by USPTO for Qtorin pitavastatin program

Palvella wins U.S. patent for topical statin treatment in porokeratosis, including DSAP

Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

Palvella COO Kathleen Goin disposes of common shares worth $477,449.62

Fein Reiterates Buy on PVLA, Maintains $270 Price Target on Strong QTORIN Rapamycin Data and Clear Regulatory Path

Palvella Therapeutics Is Maintained at Buy by Chardan Capital

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Palvella Therapeutics (PVLA)

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards

Chardan Capital Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Palvella Therapeutics announces new data from SELVA, TOIVA studies

Palvella says Phase 3 SELVA shows QTORIN rapamycin improves microcystic lymphatic malformations

Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations

Canaccord Genuity Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)

Palvella says Phase 2 TOIVA trial shows QTORIN rapamycin cuts venous malformation bleeding

Palvella Therapeutics Announces New Data From the Phase 2 Toiva Trial of Qtorin™ Rapamycin in Cutaneous Venous Malformations Presented at the 83Rd Annual Meeting of the Society for Investigative Dermatology

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/PVLA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":151.69,"timestamp":1789416000000,"preClose":150.13,"halted":0,"volume":223047,"hourTrading":{"tag":"盘后","latestPrice":151.7,"preClose":151.69,"latestTime":"19:59 EDT","volume":72419,"amount":10985264.12,"timestamp":1789430363855,"change":0.01,"changeRate":0.000066,"amplitude":0.000066},"delay":0,"changeRate":0.010390994471458085,"floatShares":8398100,"shares":14408407,"eps":-4.897784,"marketStatus":"Not Yet Opened","change":1.56,"latestTime":"09-14 16:00:00 EDT","open":150.14,"high":153.405,"low":150.14,"amount":33902780.43339,"amplitude":0.021748,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.897784,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":150.13,"preHourTrading":{"tag":"盘前","latestPrice":150.14,"preClose":150.13,"latestTime":"09:29 EDT","volume":372,"amount":55659.949440000004,"timestamp":1789392599521,"change":0.01,"changeRate":0.000067,"amplitude":0.009925},"postHourTrading":{"tag":"盘后","latestPrice":151.7,"preClose":151.69,"latestTime":"19:59 EDT","volume":72419,"amount":10985264.12,"timestamp":1789430363855,"change":0.01,"changeRate":0.000066,"amplitude":0.000066},"volumeRatio":1.230754,"impliedVol":0.4828,"impliedVolPercentile":0.0199},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":8398100,"roa":"-22.05%","roe":"-46.63%","lyrEps":-3.707588,"volumeRatio":1.230754,"shares":14408407,"dividePrice":0,"high":153.405,"amplitude":0.021748,"preClose":150.13,"low":150.14,"week52Low":53.3,"pbRate":"10.08","week52High":161.38,"institutionHeld":0,"latestPrice":151.69,"eps":-4.897784,"divideRate":0,"volume":223047,"delay":0,"ttmEps":-4.897784,"open":150.14,"prevYearClose":104.67,"prevWeekClose":150.13,"prevMonthClose":152.59,"prevQuarterClose":152.82,"fiveDayClose":157.24,"twentyDayClose":156.13,"sixtyDayClose":112.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"PVLA","fiscalQuarterEnding":"2026/06","expectedEps":-1.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"pre","actualEps":-1.52},{"market":"US","date":"2026-05-07","symbol":"PVLA","fiscalQuarterEnding":"2026/03","expectedEps":-0.9,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.2},{"market":"US","date":"2026-03-31","symbol":"PVLA","fiscalQuarterEnding":"2025/12","expectedEps":-0.95,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-1.08},{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1778731200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-09-11","current":-30.971149,"percent":0.281755,"low":-60.48704,"twenty":-36.771144,"median":-28.581687,"eighty":-11.069277,"high":46.119317,"avg":-20.075329,"sd":24.231606,"marketCap":2166880328},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-20","current":-29.573265,"twenty":-29.488024,"median":-17.242297,"eighty":19.914003,"marketCap":974498221},{"date":"2026-02-27","current":-60.48704,"twenty":-29.707799,"median":-17.512905,"eighty":19.303319,"marketCap":1993168926},{"date":"2026-03-06","current":-55.02714,"twenty":-30.090518,"median":-17.81704,"eighty":19.099758,"marketCap":1813254325},{"date":"2026-03-13","current":-55.699943,"twenty":-30.574428,"median":-17.963839,"eighty":19.083855,"marketCap":1835424534},{"date":"2026-03-20","current":-46.447881,"twenty":-31.137829,"median":-18.431476,"eighty":19.083855,"marketCap":1530550575},{"date":"2026-03-27","current":-47.956591,"twenty":-32.06614,"median":-18.561811,"eighty":19.083855,"marketCap":1580265588},{"date":"2026-04-02","current":-41.305964,"twenty":-32.945472,"median":-18.707892,"eighty":19.083855,"marketCap":1723078270},{"date":"2026-04-10","current":-44.675498,"twenty":-33.393759,"median":-19.095844,"eighty":19.083855,"marketCap":1863638401},{"date":"2026-04-17","current":-42.609857,"twenty":-34.004406,"median":-19.561706,"eighty":18.969352,"marketCap":1777470174},{"date":"2026-04-24","current":-43.594639,"twenty":-34.788907,"median":-19.977117,"eighty":18.816681,"marketCap":1818550375},{"date":"2026-05-01","current":-44.030414,"twenty":-35.208457,"median":-20.266831,"eighty":18.756249,"marketCap":1836728722},{"date":"2026-05-08","current":-32.885673,"twenty":-35.663927,"median":-20.816267,"eighty":1.605963,"marketCap":1621165018},{"date":"2026-05-15","current":-34.614036,"twenty":-35.663927,"median":-21.021819,"eighty":-9.854931,"marketCap":1706368150},{"date":"2026-05-22","current":-33.726646,"twenty":-35.536117,"median":-21.24101,"eighty":-10.054175,"marketCap":1662622476},{"date":"2026-05-29","current":-33.709189,"twenty":-35.477208,"median":-21.439742,"eighty":-10.192113,"marketCap":1661761905},{"date":"2026-06-05","current":-33.406604,"twenty":-35.361812,"median":-22.020353,"eighty":-10.267821,"marketCap":1646845348},{"date":"2026-06-12","current":-30.951006,"twenty":-35.258528,"median":-22.098288,"eighty":-10.422477,"marketCap":1525791744},{"date":"2026-06-18","current":-32.769429,"twenty":-35.21133,"median":-22.480166,"eighty":-10.551201,"marketCap":1615434519},{"date":"2026-06-26","current":-39.627064,"twenty":-35.273781,"median":-22.826974,"eighty":-10.561865,"marketCap":1953495352},{"date":"2026-07-02","current":-40.226416,"twenty":-35.557603,"median":-22.973101,"eighty":-10.565696,"marketCap":1983041611},{"date":"2026-07-10","current":-43.944726,"twenty":-36.020976,"median":-23.275097,"eighty":-10.575275,"marketCap":2166343157},{"date":"2026-07-17","current":-42.993327,"twenty":-36.290379,"median":-24.416835,"eighty":-10.577479,"marketCap":2119442057},{"date":"2026-07-24","current":-41.665152,"twenty":-36.922579,"median":-25.632611,"eighty":-10.577479,"marketCap":2053966975},{"date":"2026-07-31","current":-43.697421,"twenty":-37.223591,"median":-27.238059,"eighty":-10.749704,"marketCap":2154151740},{"date":"2026-08-07","current":-36.182159,"twenty":-37.223591,"median":-27.449273,"eighty":-10.795027,"marketCap":2232294496},{"date":"2026-08-14","current":-36.560492,"twenty":-37.14313,"median":-27.55759,"eighty":-10.795594,"marketCap":2255636115},{"date":"2026-08-21","current":-33.297956,"twenty":-36.964247,"median":-27.969419,"eighty":-10.845405,"marketCap":2054350670},{"date":"2026-08-28","current":-35.107881,"twenty":-36.922579,"median":-28.427404,"eighty":-10.961312,"marketCap":2166015824},{"date":"2026-09-04","current":-36.30827,"twenty":-36.860843,"median":-28.502544,"eighty":-11.000041,"marketCap":2240075036},{"date":"2026-09-11","current":-35.121893,"twenty":-36.771144,"median":-28.581687,"eighty":-11.069277,"marketCap":2166880328}],"updateTime":1789449371509},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640909968","title":"Palvella Therapeutics - on Track to Submit Nda for Qtorin Rapamycin in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640909968","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640909968?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:30","pubTimestamp":1780486200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA1GGYLM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640665909","title":"Palvella Therapeutics Announces Completion of FDA Pre-Nda Meeting for Qtorin™ Rapamycin in Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2640665909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640665909?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:30","pubTimestamp":1780486200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA1GGYLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910966","title":"Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910966","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910966?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:30","pubTimestamp":1780399800,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., June  02, 2026  (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commerciali","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305033/0/en/Palvella-Therapeutics-to-Participate-in-the-Goldman-Sachs-47th-Annual-Global-Healthcare-Conference-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","LU2750360997.AUD","LU0742534661.SGD","HCSG","LU1894683264.USD","LU1791807156.HKD","LU2750360641.GBP","LU0345770993.USD","LU0096364046.USD","LU1868836757.USD","LU2471134523.USD","LU2471134796.USD","LU0942090050.USD","LU0251142724.SGD","BK4550","BK4552","IE00BSNM7G36.USD","LU0029874061.USD","IE0034235188.USD","IE00B19Z3581.USD","LU2237443978.SGD","LU0868494708.USD","LU1668664300.SGD","LU0128526141.USD","IE0004091025.USD","LU2237443622.USD","BK4585","BK4127","PVLA","LU0106831901.USD","LU1868836914.USD","LU2471134879.HKD","GSX","LU1868837136.USD","LU1894683348.USD","IE00BFXG1179.USD","LU0251131958.USD","XLV","BK4137","BK4516","BK4504","LU0048573561.USD","IE0004086264.USD","LU1868836591.USD","LU2237443465.HKD","LU2237438978.USD","XBI","LU0061475181.USD","LU1868837300.USD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638642756","title":"Palvella Therapeutics Inc : Stephens Raises Target Price to $229 From $220","url":"https://stock-news.laohu8.com/highlight/detail?id=2638642756","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638642756?lang=en_us&edition=fundamental","pubTime":"2026-05-28 18:18","pubTimestamp":1779963539,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN4250A7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638768000","title":"Mizuho Securities Sticks to Their Buy Rating for Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638768000","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638768000?lang=en_us&edition=fundamental","pubTime":"2026-05-28 02:15","pubTimestamp":1779905716,"startTime":"0","endTime":"0","summary":"In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Palvella Therapeutics, with a price target of $240....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638009295","title":"Palvella Therapeutics issued patent by USPTO for Qtorin pitavastatin program","url":"https://stock-news.laohu8.com/highlight/detail?id=2638009295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638009295?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:11","pubTimestamp":1779883913,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced the issuance of U.S. Patent No. 12,636,273 by the United States Patent and Trademark Office. The issued pate...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-issued-patent-by-uspto-for-qtorin-pitavastatin-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-issued-patent-by-uspto-for-qtorin-pitavastatin-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638029435","title":"Palvella wins U.S. patent for topical statin treatment in porokeratosis, including DSAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2638029435","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638029435?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:32","pubTimestamp":1779881560,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics secured a Yale-licensed U.S. patent covering topical HMG-CoA reductase inhibitors, including pitavastatin, for porokeratosis.Patent protection runs into 2043, strengthening IP around its investigational QTORIN pitavastatin program for disseminated superficial actinic porokeratosis.Phase 2 trial in DSAP planned for the second half of 2026, targeting a rare premalignant skin disease with no FDA-approved therapies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL8kZ3rX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014021.USD","LU2210150020.SGD","NDAQ","IE00BN0W2T93.GBP","LU2095319765.USD","BK4588","SG9999014013.SGD","PVLA","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4585","SG9999014039.USD","BK4112","SG9999014005.SGD","LU0314104364.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638502169","title":"Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043","url":"https://stock-news.laohu8.com/highlight/detail?id=2638502169","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638502169?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:30","pubTimestamp":1779881400,"startTime":"0","endTime":"0","summary":"Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP) DSAP is a serious, rare,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301826/0/en/Palvella-Therapeutics-Strengthens-QTORIN-Pitavastatin-Intellectual-Property-with-Yale-Licensed-U-S-Patent-Providing-Protection-into-2043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637341038","title":"Palvella COO Kathleen Goin disposes of common shares worth $477,449.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2637341038","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637341038?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:06","pubTimestamp":1779480380,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Chief Operating Officer Kathleen Goin exercised stock options on May 20, 2026, acquiring 4,302 common shares at exercise prices of USD 7.14 and USD 9.08.She sold 4,302 common shares the same day at weighted average prices of USD 110.35 and USD 111.3.Her direct holding in common stock fell to zero following the transactions.She reported 21,521 stock options beneficially owned following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL60tZrL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Palvella COO Kathleen Goin disposes of common shares worth $477,449.62","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637308358","title":"Fein Reiterates Buy on PVLA, Maintains $270 Price Target on Strong QTORIN Rapamycin Data and Clear Regulatory Path","url":"https://stock-news.laohu8.com/highlight/detail?id=2637308358","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637308358?lang=en_us&edition=fundamental","pubTime":"2026-05-21 23:45","pubTimestamp":1779378319,"startTime":"0","endTime":"0","summary":"Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Palvella Therapeutics and keeping the price target at $270.00. Andrew Fein has ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/fein-reiterates-buy-on-pvla-maintains-270-price-target-on-strong-qtorin-rapamycin-data-and-clear-regulatory-path-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/fein-reiterates-buy-on-pvla-maintains-270-price-target-on-strong-qtorin-rapamycin-data-and-clear-regulatory-path-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637394503","title":"Palvella Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2637394503","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637394503?lang=en_us&edition=fundamental","pubTime":"2026-05-21 21:10","pubTimestamp":1779369000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 21, 2026 09:10 ET (13:10 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637933930","title":"Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637933930","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637933930?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:50","pubTimestamp":1779367854,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dyne Therapeutics (DYN) and Palvella Therapeutics (P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dyne-therapeutics-dyn-and-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dyne-therapeutics-dyn-and-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","LU0029874061.USD","XBI","XLV","BK4137","LABU","BK4581","PVLA","DYN","BK4588","BK4139","HCSG","LU0128526141.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333392","title":"Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333392","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333392?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:30","pubTimestamp":1779363000,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., May  21, 2026  (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299219/0/en/Palvella-Therapeutics-Named-Healthcare-Life-Sciences-Company-of-the-Year-at-the-Philadelphia-Alliance-for-Capital-and-Technologies-PACT-Ecosystem-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4137","HCSG","BK4581","BK4585","XBI","XLV","LABU","PVLA","BK4139","LU0029874061.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637080858","title":"Chardan Capital Keeps Their Buy Rating on Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637080858","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637080858?lang=en_us&edition=fundamental","pubTime":"2026-05-21 09:46","pubTimestamp":1779327990,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Palvella Therapeutics yesterday and set a price target of $240.00. According to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-keeps-their-buy-rating-on-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-keeps-their-buy-rating-on-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637587308","title":"Palvella Therapeutics announces new data from SELVA, TOIVA studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2637587308","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637587308?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:40","pubTimestamp":1779309611,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced new clinical data from the Phase 3 SELVA and Phase 2 TOIVA studies were reported at the International Societ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-announces-new-data-from-selva-toiva-studies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-announces-new-data-from-selva-toiva-studies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637987390","title":"Palvella says Phase 3 SELVA shows QTORIN rapamycin improves microcystic lymphatic malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2637987390","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637987390?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:32","pubTimestamp":1779309123,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics reported new data from its SELVA Phase 3 trial in microcystic lymphatic malformations, presented at the ISSVA World Congress 2026.The update showed broad clinical improvement across assessed patients, including meaningful reductions in hard-to-manage bleeding or leaking, with high patient-reported satisfaction.Independent blinded review supported disease stability before treatment, followed by clear improvement on therapy, reinforcing the trial’s baseline-controlled design.New TOIVA Phase 2 data in cutaneous venous malformations, also presented at the meeting, showed sustained improvements that strengthened with longer treatment duration.An NDA filing for QTORIN rapamycin in microcystic lymphatic malformations is planned for 2H 2026, with a Phase 3 start in cutaneous venous malformations targeted for 2H 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL2hJ9tC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","SG9999014013.SGD","SG9999014021.USD","BK4588","LU0314104364.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4139","PVLA","NDAQ","LU2095319765.USD","BK4112","IE00BKPKM429.USD","SG9999014039.USD","BK4585","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637873245","title":"Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2637873245","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637873245?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:30","pubTimestamp":1779309000,"startTime":"0","endTime":"0","summary":"In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as “Much Improved” (+2) or “Very Much Improved” (+3) on the Microcystic Lymphatic Malformation Investigator Global Asses","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298897/0/en/Palvella-Therapeutics-Presents-New-SELVA-and-TOIVA-Data-at-the-2026-International-Society-for-the-Study-of-Vascular-Anomalies-World-Congress-Supporting-QTORIN-Rapamycin-as-a-Potent.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","PVLA","BK4139","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078355","title":"Canaccord Genuity Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078355","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078355?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:37","pubTimestamp":1779104265,"startTime":"0","endTime":"0","summary":"In a report released today, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Palvella Therapeutics, with a price target of $227.00. A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635961089","title":"Palvella says Phase 2 TOIVA trial shows QTORIN rapamycin cuts venous malformation bleeding","url":"https://stock-news.laohu8.com/highlight/detail?id=2635961089","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635961089?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844647,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics disclosed new Phase 2 TOIVA trial results for topical QTORIN rapamycin in cutaneous venous malformations, presented at Society for Investigative Dermatology annual meeting.Study readout showed improvement in bleeding among patients who entered trial with active bleeding, supporting potential use in a symptom that can drive medical visits and procedures.Patients also reported high treatment satisfaction, aligning with clinician-assessed improvements and strengthening positioning for later-stage development.Management framed program as a potential first FDA-approved option for cutaneous venous malformations in US, a claim that could shape commercial strategy if confirmed in future trials.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDLbN3qGG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","NDAQ","SG9999014021.USD","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","PVLA","IE00B3QW5Z07.USD","BK4139","BK4112","SG9999014039.USD","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4585","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635608089","title":"Palvella Therapeutics Announces New Data From the Phase 2 Toiva Trial of Qtorin™ Rapamycin in Cutaneous Venous Malformations Presented at the 83Rd Annual Meeting of the Society for Investigative Dermatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2635608089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635608089?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA5HKHSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":138,"code":"91000000","status":"200"}]}}